【摘要】 为进行康莱特注射液Ⅲ期检验临床抗癌疗效及病理学变化，北京胸部肿瘤结核病医院等单位联合对７５例原发性肺癌病例进行了观察。其中术前用康莱特治疗４５例，未治疗３０例。结果显示，康莱特治疗组有效率达２０％（９／４５），临床未见明显毒副作用。术后病理观察，肿瘤组织坏死面积达２５％以上者占６２２２％（２８／４５），对照组为２６６７％（８／３０），两组差别明显（Ｐ＜００５）。根据癌细胞组织对康莱特治疗反应程度不同分为０级（无反应）、Ⅰ级（轻度）、Ⅱ级（中度）和Ⅲ级（重度）。康莱特组以Ⅰ级和Ⅱ级居多，占９５６％（４３／４５），而对照组以０级和Ⅰ级为主，占８６７％（２６／３０），两组比较差别显著（Ｐ＜００１）。依据临床及病理学观察结果，认为康莱特注射液对治疗原发性肺癌有一定的疗效。更多还原

【Abstract】 Abstract For phase III clinical trial, we observed 75 patients with primary lung cancer Of these patients 45 had a combination of Kang-Lai-Te therapy prior to surgical operation named as the treatment group, 30 had surgery alone as control The result showed that the response rate (CR+PR) of the therapy group was 20%without any toxicity or side effect Histologic assessment of the tumor on the specimens showed that tumor necrotic area in excess of 25%was 6222%in the trial group compared to 2662%in the control The difference was statistically significant (P< 005) These results suggest that Kang-Lai-Te injection has a favorable anti-cancer effect in the treatment of primary lung cancer更多还原